This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

HCA Gives Shareholders Chest Pain: Street Whispers

The question is whether the practice -- a private equity industry standard called a "dividend recapitalization" -- is suitable for ordinary stockholders now that HCA is a U.S.-listed company with a market cap nearing $12 billion. Those questions are only accentuated by HCA's debt load, leverage ratios, shareholder equity deficit and junk bond ratings.

In maintaining a sub-investment grade B+ rating on HCA's billions in newly issued and outstanding debt, ratings agency Standard & Poor's notes the company's private-equity-like dividend practices as a key risk.

"Because HCA has an extensive history of large shareholder distributions as a public company, we believe dividends to its equity partners and shareholders may take precedence over sustainable debt reduction, keeping it highly leveraged," S&P credit analyst David Peknay wrote in a November 2011 ratings opinion.

In 2010, the calendar year prior to HCA's IPO, Bain and KKR paid themselves total dividends in excess of $4 billion, nearly matching their initial combined equity investment of $5.5 billion. That practice of plowing cash flow and earnings back to investors instead of balance sheet repair from the debt-laden 2006 buyout appears to be a key to HCA's financial management, even as it becomes majority-owned by U.S. stock investors.

Because the bulk of HCA's debts come due at the end of the decade and the company generates industry-leading cash flow and profit, analysts don't appear worried about what would normally be considered an outrageous debt. No analysts covering HCA give it a "sell" rating. Meanwhile, they hold 20 "buy" recommendations and four "holds," according to Bloomberg data.

In the aftermath of Monday's New York Times report, some covering the stock expect allegations of abusive cardiology practices and aggressive revenue policies to eventually blow over. In fact, they point to second-order risks that are seemingly unrelated to the Times allegations, HCA's management practices, or the issue of medical fraud.

"Media scrutiny will likely also highlight Bain Capital's relationship to HCA given how critical the Obama campaign has been of Romney and his work at Bain Capital," wrote Jefferies analyst Arthur Henderson in an Aug 6 report that maintained HCA's "buy" rating, but cut its price target nearly 12% to $30. "Expect anxieties to run high this week, but we think they will abate shortly, sooner rather than later," added Henderson, who noted that the reports, and a prospective DoJ inquiry clouded HCA's strong second-quarter earnings, in an assessment that mirrored consensus.

Whatever the outcome of HCA's cardiology practices, it's resoundingly clear that the company's titanic debt stock shouldn't be expected to "abate" any time soon.

That's where investors should pay attention.

-- Written by Antoine Gara in New York
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HCA $77.89 0.00%
KKR $17.44 0.00%
AAPL $110.38 0.00%
FB $92.07 0.00%
GOOG $626.91 0.00%


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs